EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer

Kate L Mahon iD, Sarah Im Sutherland, Hui Ming Lin iD, Martin R Stockler, Howard Gurney, Girish Mallesara, Karen Briscoe iD, Gavin Marx, Celestia S Higano, Johann S de Bono, Kim N Chi, Georgina Clark und 3 weitere

The Prostate · 2024

DOI: 10.1002/pros.24691 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Prostate, 2024. Verfasst von Kate L Mahon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Chris O'Brien Lifehouse, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Docetaxel, Prostatic Neoplasms, Castration-Resistant, Biomarkers, Tumor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Movember Foundation, Cancer Institute NSW, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated circulating growth differentiation factor (GDF15/MIC‐1), interleukin 4 (IL4), and IL6 levels were associated with resistance to docetaxel in an exploratory cohort of men with metastatic castration‐resistant prostate cancer (mCRPC). This study aimed to establish level 2 evidence of cytokine biomarker utility in mCRPC.

Methods

IntVal: Plasma samples at baseline (BL) and Day 21 docetaxel ( n = 120). ExtVal: Serum samples at BL and Day 42 of docetaxel ( n = 430). IL4, IL6, and GDF15 levels were measured by ELISA. Monocytes and dendritic cells were treated with 10% plasma from men with high or low GDF15 or recombinant GDF15.

Results

IntVal: Higher GDF15 levels at BL and Day 21 were associated with shorter overall survival (OS) (BL; p = 0.03 and Day 21; p = 0.004). IL4 and IL6 were not associated with outcomes. ExtVal: Higher GDF15 levels at BL and Day 42 predicted shorter OS (BL; p < 0.0001 and Day 42; p < 0.0001). Plasma from men with high GDF15 caused an increase in CD86 expression on monocytes ( p = 0.03), but was not replicated by recombinant GDF15.

Conclusions

Elevated circulating GDF15 is associated with poor prognosis in men with mCRPC receiving docetaxel and may be a marker of changes in the innate immune system in response to docetaxel resistance. These findings provide a strong rationale to consider GDF15 as a biomarker to guide a therapeutic trial of drugs targeting the innate immune system in combination with docetaxel in mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15DocetaxelProstatic Neoplasms, Castration-ResistantBiomarkers, TumorAntineoplastic AgentsHumansMaleAgedMiddle AgedInterleukin-4Interleukin-6Drug Resistance, NeoplasmMonocytes

Stichwörter der Autor:innen

biomarkerdocetaxelgrowth differentiation factor 15metastatic castration‐resistant prostate cancerprognosistherapeutic response

Substanzen

Growth Differentiation Factor 15DocetaxelGDF15 protein, humanBiomarkers, TumorAntineoplastic AgentsInterleukin-4Interleukin-6

Autor:innen und Institutionen

  • Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Prostate Cancer Research Group, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Cancer Research Group, The ANZAC Research Institute, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, University of NSW, Sydney, New South Wales, Australia.
  • Westmead Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Kate L Mahon, Hui Ming Lin, Karen Briscoe

Förderung

  • Movember Foundation
  • Cancer Institute NSW
  • National Health and Medical Research Council
  • Prostate Cancer Foundation of Australia

Zitieren

APA

Mahon, K. L., Sutherland, S. I., Lin, H. M., Stockler, M. R., Gurney, H., Mallesara, G., Briscoe, K., Marx, G., Higano, C. S., de Bono, J. S., Chi, K. N., Clark, G., Breit, S. N., Brown, D. A., & Horvath, L. G. (2024). Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer. The Prostate. https://doi.org/10.1002/pros.24691

Vancouver

Mahon KL, Sutherland SI, Lin HM, Stockler MR, Gurney H, Mallesara G, et al. Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer. The Prostate. 2024. doi:10.1002/pros.24691

BibTeX
@article{Mahon2024,
  author = {Mahon, Kate L and Sutherland, Sarah Im and Lin, Hui Ming and Stockler, Martin R and Gurney, Howard and Mallesara, Girish and Briscoe, Karen and Marx, Gavin and Higano, Celestia S and de Bono, Johann S and Chi, Kim N and Clark, Georgina and Breit, Samuel N and Brown, David A and Horvath, Lisa G},
  title = {Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24691}
}
Kostenlos starten →